675882-71-0

Basic information

• Product Name: Methyl 4-(butyrylamino)-5-methyl-3-aminobenzoate
• Synonyms: 3-Amino-5-methyl-4-[(1-oxobutyl)amino]-benzoic acid methyl ester;Methyl 4-(butyrylamino)-5-methyl-3-aminobenzoate;Methyl-4-(Butyrylamino)-3-Methyl-5-Aminobenzoate;3-Methyl-4-butyrylamido-5-aminobenzoic acid methyl ester;4-[(1-oxobutyl)amino]-, methyl ester;Benzoic acid, 3-amino-5-methyl-;Methyl 3-aMino-4-butyraMido-5-Methylbenzoate
• CAS NO: 675882-71-0
• Molecular Formula: C₁₃H₁₈N₂O₃
• Molecular Weight: 250.29
• EINECS: 1312995-182-4
• Mol File: 675882-71-0.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 447.456 °C at 760 mmHg
• Flash Point: 224.414 °C
• Appearance: /
• Density: 1.180
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.581
• PKA: 14.16±0.70(Predicted)
• CAS DataBase Reference: Methyl 4-(butyrylamino)-5-methyl-3-aminobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-(butyrylamino)-5-methyl-3-aminobenzoate(675882-71-0)
• EPA Substance Registry System: Methyl 4-(butyrylamino)-5-methyl-3-aminobenzoate(675882-71-0)

Safety Data

• Hazardous Substances Data: 675882-71-0(Hazardous Substances Data)

Usage

Description

Methyl 4-(butyrylamino)-5-methyl-3-aminobenzoate is an organic compound with a complex chemical structure. It is characterized by the presence of an amide group, which is formed by the reaction of a carboxylic acid with an amine. Methyl 4-(butyrylamino)-5-methyl-3-aminobenzoate has potential applications in the pharmaceutical industry due to its unique chemical properties.

Uses

Used in Pharmaceutical Industry:
Methyl 4-(butyrylamino)-5-methyl-3-aminobenzoate is used as an intermediate in the synthesis of compounds with medicinal applications. Its unique chemical structure allows it to be a valuable building block in the creation of new drugs, potentially leading to the development of novel therapeutic agents.
Methyl 4-(butyrylamino)-5-methyl-3-aminobenzoate is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its application in this industry is due to its potential to contribute to the development of new medications with improved efficacy and safety profiles.

InChI:InChI=1/C13H18N2O3/c1-4-5-11(16)15-12-8(2)6-9(7-10(12)14)13(17)18-3/h6-7H,4-5,14H2,1-3H3,(H,15,16)

Upstream product

• 152628-01-8 4-butyrylamino-3-methyl-5-nitro-benzoic acid methyl ester 
• 3113-71-1 3-methyl-4-nitrobenzoic acid 
• 301533-59-5 methyl 4-(n-butyrylamino)-3-methylbenzoate 
• 24078-21-5 methyl 3-methyl-4-nitrobenzoate 
• 18595-14-7 methyl 4-amino-3-methylbenzoate 

Downstream Products

• 152628-00-7 4-methyl-2-propyl-1H-benzimidazole-6-carboxylic acid methyl ester 
• 152628-03-0 4-methyl-2-n-propyl-1H-benzimidazole-6-carboxylic acid 
• 675882-83-4 4'-[4-methyl-6-(7-methyl-benzooxazol-2-yl)-2-propyl-benzoimidazol-1-ylmethyl]-biphenyl-2-carbonitrile 
• 675882-77-6 4'-[[2-n-propyl-4-methyl-6-(5-methylbenzoxazol-2-yl)-benzimidazol-1-yl]methyl]-2-cyanobiphenyl 
• 675882-75-4 methyl 4'-[[2-n-propyl-4-methyl-6-(5-methylbenzoxazol-2-yl)-benzimidazol-1-yl]methyl]biphenyl-2-carboxylate 
• 675882-81-2 4'-[4-methyl-6-(7-methyl-benzooxazol-2-yl)-2-propyl-benzoimidazol-1-ylmethyl]-biphenyl-2-carboxylic acid methyl ester 

Relevant articles and documents

Synthesis method of telmisartan intermediate

The invention discloses a synthesis method of a telmisartan intermediate, and belongs to the technical field of medicine synthesis. The preparation method comprises the following steps: by taking methyl 3-methyl-4-butyrylamino-5-nitrobenzoate as a starting material, carrying out reduction reaction in an alcohol solvent environment at the adding temperature of 40-70 DEG C and the reaction temperature of 40-70 DEG C under the joint participation of a nitro reducing agent and hydrazine hydrate, and filtering and spin-drying after the reaction is completed, so as to obtain 3-methyl-4-butyrylamino-5-aminobenzoic acid methyl ester. When the method is used for reducing nitro, the selectivity of reducing groups is high, raw materials are easy to obtain, pollution is small, and the requirement for equipment is low; and the method is low in cost, green, safe, simple and convenient to operate and easy to realize industrial production.

Novel preparation method of antihypertensive drug telmisartan intermediate

The invention relates to an electric reduction preparation method of aminobenzoic acid represented by formula I and ester thereof. The preparation reaction of the method is shown in the description; and in the reaction formula, R is selected from hydrogen, a methyl group, an ethyl group, a benzyl group, a C3 or C4 straight-chain alkyl or branched-chain alkyl group, -NO2 is selected from 4-NO2 or 5-NO2, and Y is selected from H or 4-NHCOC3H7-n. The electroreduction preparation method of aminobenzoic acid and ester I thereof is characterized in that in a separated electrolytic cell, an acidic solution of nthe itrobenzoic acid and ester III thereof is taken as a catholyte; the voltage of a cathode working electrode relative to a reference electrode is 1.00-2.50 V; and an anolyte is an acidicsolution, the current density is 25.0-250.0 mA/cm, and the electrolysis temperature is 15-90 DEG C.

N-Phenyl indole derivatives as AT1 antagonists with anti-hypertension activities: Design, synthesis and biological evaluation

The design, synthesis, in vitro and in vivo evaluation of 6-substituted benzimidazole with 1, 4-disubsituted or 1, 5-disubsituted indole derivatives as novel angiotensin II receptor antagonists are outlined. Radioligand binding assays showed that several 6-substituted benzimidazole derivatives displayed high affinities binding to the angiotensin II type 1 receptor at the same order of magnitude to telmisartan. The biological evaluation on spontaneously hypertensive rats showed that 2-[4-[[2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)benzimidazole-1-yl]methyl]-1H-indol-1-yl]benzoic acid, 1c, could cause significant decrease on MBP in a dose dependent manner. Its maximal response lowered 53 mmHg of MBP at 5 mg/kg and 64 mmHg of MBP at 10 mg/kg after oral administration, and the significant antihypertensive effect lasted beyond 24 h, which was better than both losartan and telmisartan. A study designed to determine acute toxicity showed that 1c had low acute toxicity with no significant changes in the weight and no obvious untoward reactions. The encouraging results make 1c an effective and durable anti-hypertension drug candidate and deserve further investigation for therapeutic application.